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ABSTRACT 
 
Drug Utilization Study of Oral Antidiabetic (OAD) 
 in Patient with Type 2 Diabetes Mellitus 
(Studied in Outpatient Unit Airlangga Hospital Surabaya) 
 
Laily Asmaningsih 
 
Diabetes mellitus is the chronic disorder emerging as a major 
world health problem which increase the rate of morbidity and mortality. In 
most cases, patients with OAD therapy will require not only an increase 
dose, but also the addition of a second and third OAD or combination 
OAD-insulin. The aim of this study are to know profile utilization of OAD 
drugs in patients with type 2 diabetes mellitus, correlate between a 
utilization profile of OAD with clinical conditions, especially blood glucose 
level and identify drug related problems (DRPs) in patients with oral 
diabetic therapy. It was an observational-descriptive study, data was 
collected cross-sectional with non random-purposive sampling method in 
the period March 2016 until May 2016 in the Outpatient Unit Airlangga 
Hospital Surabaya. The results of observational study on  240  patients 
showed  oral antidiabetic therapy that used in this study, 36.67% patients 
used OAD (monotherapy or combination) and 63% patients used  a 
combination of OAD-insulin. In this study, OAD that commonly used was 
biguanid (metformin) 67.33% patients, sulfonylureas (glimepiride, 
glibenklamid, gliclazide and gliquidon) 65.83% patients, alpha-glucosidase 
inhibitor (Acarbose) 27.50% patients, thiazolidinedion (pioglitazon) 
10.00% patients and DPP-4 inhibitor (linagliptin) 0.42% patient. Based on 
the glycemic targets, patients with blood glucose levels achieved with 
glycemic targets are 25.50% of patients, which was not achieved in 75.50% 
of patients and hypoglycemia 4.00% of patients. Drug related problems can 
be identified is such as adverse drug reaction that is flatulence (7.92%), 
nausea (6.25%), metallic taste (0.83%), bloating (0.83%) and hypoglycemia 
(2.5%) and potential drug interactions (23.75%). 
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